Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects
Modulation of Biomarkers and Gene Expression by Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults, aged 21 years or more with either diabetes or metabolic syndrome. metabolic syndrome defined by NCEP/ATPIII criteria; must have 3 out of 5 of the following risk factors: 1.central obesity, men-greater than or equal to 40 inches, women-greater than or equal to 35 inches; 2.fasting blood TG greater than or equal to 150mg/dl or be taking TG lowering medications; 3. blood HDL cholesterol, men less than 40 mg/dl, women less than 50 mg/dl; 4. blood pressure greater than or equal to 130/85 or on HTN medication 5. fasting glucose greater than or equal to 100 mg/dl.
- participants on statins or glucose lowering drugs if dosages are stable for 3 months
Exclusion criteria
- children/young adults less than 21 years of age
- currently using anti-inflammatory drugs including NSAIDS, oral/IV steroids or injection antiinflammatory drugs(for RA), aspirin greater than 100mg/day
- taking leukotriene receptor antagonists ( montelukast), tylenol or nasal/inhaled steroids OK.
- currently using niacin, fibrates or fish oil
- blood pressure greater than 170/100
- HB1Ac greater than 10%
- TG greater than 500 mg/dl
- myocardial infarction/vascular surgery/stroke within the past year
- any stage II,III,IV heart failure
- prior cholecystectomy
- end stage renal disease
- BMI less than 23 or greater than 45
- pregnancy
- alcohol use greater than 14 drinks per week
- current self reported tobacco or illicit drug use
- intolerance or allergy to fish oil
- participants taking insulin on QD or BID doses, stable for 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: borage and echium oil combination
borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
|
borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
Other Names:
|
|
Active Comparator: fish oil
Croda 18:12 fish oil
|
1.6g/day EPA and 1.08g/day DHA
Other Names:
|
|
Placebo Comparator: corn oil
|
contains 4.5 g/day linoleic acid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting Insulin
Time Frame: baseline
|
baseline
|
|
|
Fasting Insulin
Time Frame: 4 weeks and 8 weeks combined
|
Fasting insulin data at 4 and 8 weeks was averaged.
|
4 weeks and 8 weeks combined
|
|
hsCRP
Time Frame: baseline
|
Changes in high sensitive C-reactive protein (hsCRP) were assessed.
|
baseline
|
|
hsCRP
Time Frame: 4 weeks and 8 weeks combined
|
Changes in high sensitive C-reactive protein (hsCRP) were assessed and data at 4 and 8 weeks was averaged..
|
4 weeks and 8 weeks combined
|
|
Leptin
Time Frame: baseline
|
baseline
|
|
|
Leptin
Time Frame: 4 weeks and 8 weeks combined
|
Data at 4 and 8 weeks was averaged.
|
4 weeks and 8 weeks combined
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum Fatty Acids
Time Frame: baseline
|
baseline
|
|
|
Serum Fatty Acids
Time Frame: 4 weeks and 8 weeks combined
|
Data at 4 and 8 weeks was averaged.
|
4 weeks and 8 weeks combined
|
|
Pro and Anti-inflammatory Cytokines
Time Frame: baseline
|
baseline
|
|
|
Pro and Anti-inflammatory Cytokines
Time Frame: 4 weeks and 8 weeks combined
|
4 weeks and 8 weeks combined
|
|
|
Fasting Glucose
Time Frame: baseline
|
baseline
|
|
|
Fasting Glucose
Time Frame: 4 weeks and 8 weeks combined
|
Data at 4 and 8 weeks was averaged.
|
4 weeks and 8 weeks combined
|
|
Hemoglobin Levels
Time Frame: baseline
|
baseline
|
|
|
Hemoglobin Levels
Time Frame: 4 weeks and 8 weeks combined
|
Data at 4 and 8 weeks was averaged.
|
4 weeks and 8 weeks combined
|
|
Adipose Derived Cytokines
Time Frame: 4 weeks
|
4 weeks
|
|
|
PBMC Gene Expression
Time Frame: baseline
|
baseline
|
|
|
PBMC Gene Expression
Time Frame: 4 weeks
|
4 weeks
|
|
|
SNPs in DNA of Selected Genes
Time Frame: baseline
|
baseline
|
|
|
SNPs in DNA of Selected Genes
Time Frame: 4 weeks
|
4 weeks
|
|
|
PBMC Leukotriene Stimulation
Time Frame: baseline
|
baseline
|
|
|
PBMC Leukotriene Stimulation
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Floyd(Ski) H Chilton, Ph.D., Wake Forest University Health Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB00007488
- P50 AT 0027820 (Other Grant/Funding Number: NCCAM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.